Product Overview
The Zyvex Pharmaceuticals Nolvadex box holds one hundred tablets of 20 mg tamoxifen citrate. The molecule is a selective estrogen receptor modulator and a prodrug: the liver turns it into a metabolite with a half-life near two weeks, so the tissue effect sits at a fairly even level on one tablet a day and keeps working after the bottle is back in the drawer.
Its two roles look different but come from the same action. In breast tissue the tablet takes the receptor and stops estrogen from driving the gland, which is why it is used both to prevent and to treat the swelling and tenderness that a converting course can produce. In the hypothalamus and pituitary the same blockade makes the brain read estrogen as low, so it releases more luteinizing hormone and follicle stimulating hormone, and natural testosterone production climbs back.
What it never does is remove estrogen. The blood level of estradiol is untouched, which separates this product from an inhibitor and explains why high blood pressure, fluid and lipid effects from estrogen are not fixed here. Users who expect a lump to dissolve overnight are expecting the wrong mechanism; the tablet works on the receptor, and a mass that is already fibrous is a surgical conversation, not a tablet one. On a plan that includes Methandienone or Oxymetholone, the receptor block is the reason the tablet appears, and the same logic covers a nineteen-nor plan built on Nandrolone Esters, where breast symptoms arrive through a second route as well.
Dosage Protocol
The figures below are the reference values for the substance, covering both the prevention role on a course and the recovery role after one.
| Level | Amount | Length | Note |
| Recovery standard | 20-40 mg daily | 4 weeks | The ordinary shape of a recovery course |
| Classic taper | 40 mg for one week, then 20 mg | 4 weeks | The pattern known by its two numbers |
| Long suppression | 40 mg for one week, then 20 mg | 4-6 weeks | Used where a long ester was still clearing when the course began |
| Prevention on cycle | 10-20 mg daily | While the converting compound runs | A smaller amount used for breast symptoms rather than for recovery |
| Female | Not a sports protocol | - | Medically used in breast cancer treatment |
| Route | Oral tablet | Once daily | Slow metabolism of the metabolite keeps the level steady through the day |
One practical note governs both roles: the tablet does not lower estrogen, so the amount is not adjusted against an estrogen reading the way an inhibitor is. It is set against the symptom in front of it and against the gonadotropin result when it is being used for recovery.
Suggested Protocols
All of these are catalogue suggestions. None is a tested blueprint, and the pairings exist because the two mechanisms involved are different.
What to Expect
- Breast tenderness usually settles within the opening one to two weeks, because the tablet is competing for the receptor that the symptom runs through.
- A dose-dependent protective effect on breast tissue was shown in men over six months of treatment, which is the closest the literature comes to a direct answer for this use.
- During recovery, endogenous testosterone climbs over two to four weeks as the gonadotropin signal returns.
- The decline is slow at the end of a course, so a test taken a few days after the last tablet can still reflect the drug.
- Estradiol on a lab sheet does not fall. Anyone expecting the number to drop has misunderstood which product they are holding.
- An existing hard lump under the nipple is not a receptor problem and will not resolve on this tablet.
Side Effects and Management
Post-Cycle Therapy
The tablet is the classic recovery agent, so the schedule below frames the stage rather than the drug. Start it once the suppressive compound has cleared, hold the classic 40/20 taper for four weeks, and judge the result from blood rather than from how training feels.
